Intravascular naked DNA vaccine encoding glycoprotein B induces protective humoral and cellular immunity against herpes simplex virus type 1 infection in mice

Gene Therapy

Volumn 10, Issue 25, 2003, Pages 2059-2066

  Cui, F D ^a,b   Asada, H ^a   Kishida, T ^a   Itokawa, Y ^a   Nakaya, T ^a   Ueda, Y ^a   Yamagishi, H ^a   Gojo, S ^c   Kita, M ^a   Imanishi, J ^a   Mazda, O ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b YANBIAN UNIVERSITY   (China)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

DNA vaccination; Epstein Barr virus based plasmid vector; Glycoprotein B; Herpes simplex virus; Naked DNA

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN B; INTERLEUKIN 12; NAKED DNA; NEUTRALIZING ANTIBODY; PLASMID DNA; PLASMID VECTOR; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; EPSTEIN BARR VIRUS; FEMALE; GENE EXPRESSION; GENETIC CODE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; INOCULATION; LATENT VIRUS INFECTION; LETHAL DOSE; LYMPHOCYTE PROLIFERATION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; VACCINATION;

ANIMALS; ANTIBODY FORMATION; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; GENE THERAPY; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HERPESVIRUS 4, HUMAN; IMMUNITY, CELLULAR; INJECTIONS, INTRAVENOUS; INTERFERON TYPE II; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; VACCINES, DNA; VIRAL ENVELOPE PROTEINS; VIRUS LATENCY;

ANIMALIA; DNA VIRUSES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 4; SIMPLEXVIRUS;

EID: 10744222639     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302114     Document Type: Article

References (65)

1. Tighe H, Corr M, Roman M, Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol Today 1998; 19: 89-97.
2. Wolff JA et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-1468.
3. Liu F, Song YK, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Therapy 1999; 6: 1258-1266.
4. Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999; 10: 1735-1737.
5. Cui FD et al. Highly efficient gene transfer into murine liver achieved by intravenous administration of naked Epstein-Barr virus (EBV)-based plasmid vectors. Gene Therapy 2001; 8: 1508-1513.
6. Rouse BT et al. DNA vaccines and immunity to herpes simplex virus. Curr Top Microbiol Immunol 1998; 226: 69-78.
7. Bernstein DI, Stanberry LR. Herpes simplex virus vaccines. Vaccine 1999; 17: 1681-1689.
8. Ghiasi H et al. Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH and gI): comparative protection against lethal challenge in mice. J Virol 1994; 68: 2118-2126.
9. Hanke T, Graham FL, Rosenthal KL, Johnson DC. Identification of an immunodominant cytotoxic T-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus vectors and synthetic peptides. J Virol 1991; 65: 1177-1186.
10. Burke RL. Contemporary approaches to vaccination against herpes simplex virus. Curr Top Microbiol Immunol 1992; 179: 137-158.
11. Cose SC, Kelly JM, Carbone FR. Characterization of a diverse primary herpes simplex virus type 1 gB-specific cytotoxic T-cell response showing a preferential Vβ bias. J Virol 1995; 69: 5849-5852.
12. Fu TM et al. Induction and persistence of a cytotoxic T lymphocyte (CTL) response against a herpes simplex virus-specific CTL epitope expressed in a cellular protein. Virology 1996; 222: 269-274.
13. Mikloska Z, Cunningham AL. Herpes simplex virus type 1 glycoproteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes. J Gen Virol 1998; 79: 353-361.
14. Chen ZY et al. Linear DNAs concatemerize in vivo and result in sustained transgene expression in mouse liver. Mol Ther 2001; 3: 403-410.
15. Stoll SM et al. Epstein-Barr virus/human vector provides high-level, long-term expression of alpha1-antitrypsin in mice. Mol Ther 2001; 4: 122-129.
16. Lui VWY, He Y, Falo L, Huang L. Systemic administration of naked DNA encoding interleukin 12 for the treatment of human papillomavirus DNA-positive tumor. Hum Gene Ther 2002; 13: 177-185.
17. Itokawa Y et al. Hydrodynamics-based immuno-gene therapy against metastatic liver tumor and peritoneal carcinomatosis. Mol Ther 2002; 5: S101 (Abstract 304).
18. Kishida T et al. Complete rejection of metastatic lymphoma in murine liver by in vivo transduction with IL-21 and IL-15 genes. Mol Ther 2002; 5: S120-121, (Abstract 366).
19. Ulmer JB et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-1749.
20. Raz E et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA 1994; 91: 9519-9523.
21. Zarozinski CC et al. Protective CTL-dependent immunity and enhanced immunopathology in mice immunized by particle bombardment with DNA encoding an internal virion protein. J Immunol 1995; 154: 4010-4017.
22. Yokoyama M, Zhang J, Whitton JL. DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection. J Virol 1995; 69: 2684-2688.
23. Fuller DH, Haynes JR. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. AIDS Res Hum Retroviruses 1994; 10: 1433-1441.
24. Davis HL, Schirmbeck R, Reimann J, Whalen RG. DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein. Hum Gene Ther 1995; 6: 1447-1456.
25. Geissler M, Gesien A, Tokushige K, Wands JR. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol 1997; 158: 1231-1237.
26. Lin H et al. Expression of recombinant genes in myocardium in vivo after direct injection of DNA. Circulation 1990; 82: 2217-2221.
27. + T lymphocytes. J Immunol 1995; 155: 259-265.
28. Kriesel JD, Spruance SL, Daynes RA, Araneo BA. Nucleic acid vaccine encoding gD2 protects mice from herpes simplex virus type 2 disease. J Infect Dis 1996; 173: 536-541.
29. Kuklin N et al. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. J Virol 1997; 71: 3138-3145.
30. Mester JC, Twomey TA, Tepe ET, Bernstein DI. Immunity induced by DNA immunization with herpes simplex virus type 2 glycoproteins B and C. Vaccine 2000; 18: 875-883.
31. Caselli E et al. Mice genetic immunization with plasmid DNA encoding a secreted form of HSV-1 gB induces a protective immune response against herpes simplex virus type 1 infection. Intervirology 2001; 44: 1-7.
32. Bourne N, Stanberry LR, Bernstein DI, Lew D. DNA immunization against experimental genital herpes simplex virus infection. J Infect Dis 1996; 173: 800-807.
33. Ghiasi H et al. Vaccination of mice with herpes simplex virus type 1 glycoprotein D DNA produces low levels of protection against lethal HSV-1 challenge. Antiviral Res 1995; 28: 147-157.
34. McClements WL, Armstrong ME, Keys RD, Liu MA. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc Natl Acad Sci USA 1996; 93: 11414-11420.
35. Sin JI et al. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J Virol 1999; 73: 501-509.
36. Rous RJD et al. Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins. J Virol 1994; 68: 5685-5689.
37. Manickan E et al. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. J Leukoc Biol 1997; 61: 125-132.
38. Perelygina L, Patrusheva I, Zurkuhlen H, Hilliard JK. Characterization of B virus glycoprotein antibodies induced by DNA immunization. Arch Virol 2002; 147: 2057-2073.
39. + T cell-mediated protective immunity against herpes simplex virus-2 challenge. J Immunol 1999; 162: 2912-2921.
40. + T lymphocytes from infected mice. Characterization of T cell clones. J Immuol 1990; 145: 702-710.
41. + T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J Virol 1994; 68: 2803-2810.
42. Nugent CT, Wolcott RM, Chervenak R, Jennings SR. Analysis of cytolytic T-lymphocyte response to herpes simplex virus type 1 glycoprotein B during primary and secondary infection. J Virol 1994; 68: 7644-7648.
43. Ghiasi H et al. The importance of MHC-I and II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge. Immunology 1997; 91: 430-435.
44. Kita M, Tong LJ, Imanishi J. Induction de I'ARN messager des cytokines par I'infection de I'herpes simplex virus chez la souris. C R Soc Biol 1993; 187: 561-568.
45. Rogers JV et al. Murine response to DNA encoding herpes simplex virus type-1 glycoprotein D targeted to the liver. Vaccine 2000; 18: 1522-1530.
46. Ambinder RF et al. Functional domains of Epstein-Barr virus nuclear antigen EBNA-1. J Virol 1991; 65: 1466-1478.
47. Fischer N et al. Epstein-Barr virus nuclear antigen 1 forms a complex with the nuclear transporter karyopherin α2. J Biol Chem 1997; 272: 3999-4005.
48. Jankelevich S, Kolman JL, Bodnar JW, Miller G. A nuclear matrix attachment region organizes the Epstein-Barr viral plasmid in Raji cells into a single DNA domain. EMBO J 1992; 11: 1165-1176.
49. Wysokenski DA, Yates JL. Multiple EBNA1-binding sites are required to form an EBNA1-dependent enhancer and to activate a minimal replicative origin within oriP of Epstein-Barr virus. J Virol 1989; 63: 2657-2666.
50. Gahn TA, Sugden B. An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of Epstein-Barr virus LMP gene. J Virol 1995; 69: 2633-2636.
51. Mazda O, Satoh E, Yasutomi K, Imanishi J. Extremely efficient gene transfection into lympho-hematopoietic cell lines by Epstein-Barr virus-based vectors. J Immunol Methods 1997; 204: 143-151.
52. Maruyama-Tabata H et al. Effective suicide gene therapy in vivo by EBV-based plasmid vector coupled with polyamidoamine dendrimer. Gene Therapy 2000; 7: 53-60.
53. Harada Y et al. Highly efficient suicide gene expression in hepatocelluar carcinoma cells by Epstein-Barr virus-based plasmid vectors combined with polyamidoamine dendrimer. Cancer Gene Ther 2000; 7: 27-36.
54. Tanaka S et al. Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA-promoter. Cancer Gene Ther 2000; 7: 1241-1250.
55. Kishida T et al. In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice. Gene Therapy 2001; 8: 1234-1240.
56. Asada H et al. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex. Mol Ther 2002; 5: 609-616.
57. Nakanishi H et al. Nonviral genetic transfer of Fas ligand induced significant growth suppression and apoptotic tumor cell death in prostate cancer in vivo. Gene Therapy 2003; 10: 434-442.
58. Mazda O. Application of Epstein-Barr virus (EBV) and its genetic elements to gene therapy. In: Cid-Arregui A, Garcia-Carranca A (eds). Viral Vectors: Basic Science and Gene Therapy. Eaton Publishing: Natick, 2000, pp 325-337.
59. Mazda O. Improvement of nonviral gene therapy by Epstein-Barr virus (EBA)-based plasmid vectors. Curr Gene Ther 2002; 2: 379-392.
60. Tomiyasu K et al. Direct intra-cardiomuscular transfer of β2-adrenergic receptor gene augments cardiac output in cardiomyopathic hamsters. Gene Therapy 2000; 7: 2087-2093.
61. + cells by transfecting EBV-based episomal vectors. FEBS Lett 1998; 441: 39-42.
62. Mazda O et al. Non-viral strategies for immuno-gene therapy. In: Cancro MP (ed). Recent Research Developments in Immunology Vol. 2. Research Signpost: Trivandrum, 2000, pp 273-281.
63. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991; 108: 193-199.
64. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313: 812-815.
65. Con RW et al. Extended duration of herpes simplex virus DNA in genital lesions detected by the polymerase chain reaction. J Infect Dis 1991; 164: 757-760.